Home/Pipeline/Upstaza (eladocagene exuparvovec)

Upstaza (eladocagene exuparvovec)

Aromatic L-amino acid decarboxylase (AADC) deficiency

ApprovedCommercial

Key Facts

Indication
Aromatic L-amino acid decarboxylase (AADC) deficiency
Phase
Approved
Status
Commercial
Company

About PTC Therapeutics

PTC Therapeutics is a patient-centric, publicly traded biopharma leader dedicated to translating groundbreaking science into life-changing treatments for rare diseases. Its key achievements include commercializing a series of 'firsts' in rare disease treatment and building a diversified pipeline targeting neurological and metabolic disorders. The company's strategic direction is fueled by its deep expertise in two core scientific platforms—splicing modifiers and inflammation/ferroptosis inhibitors—and a robust global commercial infrastructure to support its mission of delivering transformative medicines worldwide.

View full company profile